Genmab A/S (OTCPK:GNMSF) is up 2% in Europe in reaction to Johnson & Johnson’s Q2 results that included a 51% jump in Darzalex (daratumumab) sales to $774M.
Genmab receives royalties on global net sales of the multiple myeloma med under an exclusive worldwide license agreement with J&J unit Janssen Biotech.
Ticker on Copenhagen exchange: (GEN:DC).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.